157 related articles for article (PubMed ID: 23723442)
1. TP53 and outcome in DLBCL: not only the coding region.
Jardin F; Coiffier B
Blood; 2013 May; 121(22):4433-4. PubMed ID: 23723442
[TBL] [Abstract][Full Text] [Related]
2. Single nucleotide variation in the TP53 3' untranslated region in diffuse large B-cell lymphoma treated with rituximab-CHOP: a report from the International DLBCL Rituximab-CHOP Consortium Program.
Li Y; Gordon MW; Xu-Monette ZY; Visco C; Tzankov A; Zou D; Qiu L; Montes-Moreno S; Dybkaer K; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Choi WW; van Krieken JH; Huang Q; Ai W; Ponzoni M; Ferreri AJ; Winter JN; Go RS; Piris MA; Møller MB; Wu L; Wang M; Ramos KS; Medeiros LJ; Young KH
Blood; 2013 May; 121(22):4529-40. PubMed ID: 23515929
[TBL] [Abstract][Full Text] [Related]
3. TP53 mutations and rituximab-CHOP.
Gisselbrecht C
Blood; 2012 Nov; 120(19):3867-9. PubMed ID: 23144158
[No Abstract] [Full Text] [Related]
4. Prognostic impact of p53 aberrations for R-CHOP-treated patients with diffuse large B-cell lymphoma.
Stefancikova L; Moulis M; Fabian P; Vasova I; Zedek F; Ravcukova B; Muzik J; Kuglik P; Vranova V; Falkova I; Hrabalkova R; Smardova J
Int J Oncol; 2011 Dec; 39(6):1413-20. PubMed ID: 21874232
[TBL] [Abstract][Full Text] [Related]
5. MDM2 phenotypic and genotypic profiling, respective to TP53 genetic status, in diffuse large B-cell lymphoma patients treated with rituximab-CHOP immunochemotherapy: a report from the International DLBCL Rituximab-CHOP Consortium Program.
Xu-Monette ZY; Møller MB; Tzankov A; Montes-Moreno S; Hu W; Manyam GC; Kristensen L; Fan L; Visco C; Dybkaer K; Chiu A; Tam W; Zu Y; Bhagat G; Richards KL; Hsi ED; Choi WW; van Krieken JH; Huang Q; Huh J; Ai W; Ponzoni M; Ferreri AJ; Wu L; Zhao X; Bueso-Ramos CE; Wang SA; Go RS; Li Y; Winter JN; Piris MA; Medeiros LJ; Young KH
Blood; 2013 Oct; 122(15):2630-40. PubMed ID: 23982177
[TBL] [Abstract][Full Text] [Related]
6. Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study.
Xu-Monette ZY; Wu L; Visco C; Tai YC; Tzankov A; Liu WM; Montes-Moreno S; Dybkaer K; Chiu A; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Zhao XF; Choi WW; Zhao X; van Krieken JH; Huang Q; Huh J; Ai W; Ponzoni M; Ferreri AJ; Zhou F; Kahl BS; Winter JN; Xu W; Li J; Go RS; Li Y; Piris MA; Møller MB; Miranda RN; Abruzzo LV; Medeiros LJ; Young KH
Blood; 2012 Nov; 120(19):3986-96. PubMed ID: 22955915
[TBL] [Abstract][Full Text] [Related]
7. CD30, another useful predictor of survival in DLBCL?
Chan WC
Blood; 2013 Apr; 121(14):2582-3. PubMed ID: 23557969
[No Abstract] [Full Text] [Related]
8. Clinical and Biologic Significance of MYC Genetic Mutations in De Novo Diffuse Large B-cell Lymphoma.
Xu-Monette ZY; Deng Q; Manyam GC; Tzankov A; Li L; Xia Y; Wang XX; Zou D; Visco C; Dybkær K; Li J; Zhang L; Liang H; Montes-Moreno S; Chiu A; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Choi WW; van Krieken JH; Huh J; Ponzoni M; Ferreri AJ; Parsons BM; Møller MB; Wang SA; Miranda RN; Piris MA; Winter JN; Medeiros LJ; Li Y; Young KH
Clin Cancer Res; 2016 Jul; 22(14):3593-605. PubMed ID: 26927665
[TBL] [Abstract][Full Text] [Related]
9. High-risk diffuse large B-cell lymphoma: can we do better than rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone?
George A; Tam CS; Seymour JF
Leuk Lymphoma; 2013 Dec; 54(12):2575-6. PubMed ID: 23597141
[No Abstract] [Full Text] [Related]
10. NF-κB p50 activation associated with immune dysregulation confers poorer survival for diffuse large B-cell lymphoma patients with wild-type p53.
Cai Q; Tu M; Xu-Monette ZY; Sun R; Manyam GC; Xu X; Tzankov A; Hsi ED; Møller MB; Medeiros LJ; Ok CY; Young KH
Mod Pathol; 2017 Jun; 30(6):854-876. PubMed ID: 28281555
[TBL] [Abstract][Full Text] [Related]
11. Genetic polymorphism at
Bashash M; Connors JM; Gascoyne RD; Meissner B; Schuetz JM; Leach S; Slack GW; Berry BR; Hu H; Sehn LH; Brooks-Wilson AR; Spinelli JJ
Haematologica; 2017 May; 102(5):e199-e202. PubMed ID: 28154089
[No Abstract] [Full Text] [Related]
12. Clinical aspects of TP53 gene inactivation in diffuse large B-cell lymphoma.
Voropaeva EN; Pospelova TI; Voevoda MI; Maksimov VN; Orlov YL; Seregina OB
BMC Med Genomics; 2019 Mar; 12(Suppl 2):35. PubMed ID: 30871527
[TBL] [Abstract][Full Text] [Related]
13. A treatment for activated B-cell-like DLBCL?
Zinzani PL
Lancet Oncol; 2014 Aug; 15(9):916-7. PubMed ID: 25042201
[No Abstract] [Full Text] [Related]
14. Targeting drug resistance to close the gap in diffuse large B-cell lymphoma.
Rund D
Leuk Lymphoma; 2014 Sep; 55(9):1966-7. PubMed ID: 24588736
[No Abstract] [Full Text] [Related]
15. Rituximab and bendamustine in patients with CD20+ diffuse large B-cell lymphoma not eligible for cyclophosphamide, doxorubicin, vincristine and prednisone-like chemotherapy.
Walter E; Schmitt T; Dietrich S; Ho A; Witzens-Harig M
Leuk Lymphoma; 2012 Nov; 53(11):2290-2. PubMed ID: 22475324
[No Abstract] [Full Text] [Related]
16. [Diffuse large B-cell lymphoma: standard treatment and research questions].
Ohmachi K
Rinsho Ketsueki; 2019; 60(9):1193-1198. PubMed ID: 31597843
[TBL] [Abstract][Full Text] [Related]
17. Is radiotherapy still necessary for diffuse large B-cell lymphoma therapy?
Mondello P; Cuzzocrea S; Pitini V; Aloisi C; Mian M
Acta Oncol; 2015 Jun; 54(6):953-5. PubMed ID: 25831143
[No Abstract] [Full Text] [Related]
18. Immunochemotherapy is the standard of care in elderly patients with diffuse large B-cell lymphoma.
Coiffier B; Salles G
Blood; 2004 Sep; 104(5):1584-5; author reply 1585-6. PubMed ID: 15317734
[No Abstract] [Full Text] [Related]
19. Clinical implications of phosphorylated STAT3 expression in De Novo diffuse large B-cell lymphoma.
Ok CY; Chen J; Xu-Monette ZY; Tzankov A; Manyam GC; Li L; Visco C; Montes-Moreno S; Dybkær K; Chiu A; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Choi WW; van Krieken JH; Huh J; Zhao X; Ponzoni M; Ferreri AJ; Bertoni F; Farnen JP; Møller MB; Piris MA; Winter JN; Medeiros LJ; Young KH
Clin Cancer Res; 2014 Oct; 20(19):5113-23. PubMed ID: 25124685
[TBL] [Abstract][Full Text] [Related]
20. Rituximab, cyclophosphamide-fractionated, vincristine, doxorubicin and dexamethasone alternating with rituximab, methotrexate and cytarabine overcomes risk features associated with inferior outcomes in treatment of newly diagnosed, high-risk diffuse large B-cell lymphoma.
Mato A; Feldman T; Zielonka T; Singavi A; Gadaletta G; Waksmundzki K; Bhattacharyya P; Chow KF; Yang X; Panush D; Agress H; Rosario M; Howlett C; Pecora A; Goy A
Leuk Lymphoma; 2013 Dec; 54(12):2606-12. PubMed ID: 23488604
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]